MediPharm Labs Corp (MEDIF)

[SpacthatAsk]

Speaking of demand, MediPharm is one of a select few pot stocks that's currently profitable on a recurring basis. Having begun its operations in Nov. 2018, it took less than two full quarters before the company was already generating an operating profit, without the aid of one-time benefits or fair-value adjustments. Considering that competitor Valens Company reported a significant increase in adjusted EBITDA during its fourth quarter, I have a strong suspicion that, even with the HEXO payment concern, this'll be the case for MediPharm, which is valued at a mere 19 times 2020's consensus profit forecast, according to Wall Street.



https://www.fool.com/investing/2020/03/03/this-is-the-top-marijuana-stock-to-buy-in-march.aspx